Candel Therapeutics (CADL) Restructuring Costs (2024 - 2025)
Candel Therapeutics (CADL) posted Restructuring Costs of $479000.0 for Q4 2025, up 8.13% sequentially from $443000.0 in Q3 2025, and down 2.24% YoY from $490000.0 in Q4 2024.
Candel Therapeutics (CADL) Restructuring Costs (2024 - 2025) Analysis & Trends
Candel Therapeutics has reported Restructuring Costs for 2 years, with the latest figure at $479000.0 in Q4 2025.
- Quarterly Restructuring Costs fell 2.24% year-over-year to $479000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 million (down 5.86% YoY) and the FY2025 annual result came in at $1.8 million, down 5.86% from the prior year.
- Restructuring Costs climbed to $479000.0 in Q4 2025 per CADL's latest filing, from $443000.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $517000.0 in Q2 2024 and troughed at $443000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 479,000.00 |
| Sep 30, 2025 | 443,000.00 |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 464,000.00 |
| Dec 31, 2024 | 490,000.00 |
| Sep 30, 2024 | 463,000.00 |
| Jun 30, 2024 | 517,000.00 |
| Mar 31, 2024 | 493,000.00 |